Regenxbio Inc (NYSE: RGNX) — Healthcare · Share Price, Chart & Market Data
About: REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
Sector: Healthcare
Industry: Biotechnology
Latest price: $8.81 (+0.57%)
RGNXRegenxbio Inc
Loading watchlist status…
Trade RGNX now
Regenxbio Inc share price
RGNX price activity
Last Price
Change (24hr)
USD (%)
Volume
Volume (4w avg)
Previous Close
N/A
Last Trade
Delayed
27 Apr, 4:40 pm GMT+0
RGNX price performance
-3.293%
5D
13.531%
1M
-35.077%
YTD
-3.505%
1Y
RGNX price fundamentals
N/A
Shares Issued
N/A
Dividends Per Share (DPS)
N/A
Earnings Per Share (EPS)
N/A
P/E Ratio
Price market cap
Market cap
N/A
NYSE rank
N/A
Sector Rank
N/A
Delayed
27 Apr, 4:40 pm GMT+0
RGNX details
RGNX Market Signals